Navigation Links
PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756
Date:5/23/2013

SCHOFIELD, Wis., May 23, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB: PMBS) a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research re-issued its research opinion on the company based on low market capitalization valuation.

Report Highlights

  • Non-Prescription, All Natural Product to Treat Migraine Headaches
  • Clinical Trials Show the Product Outperforms #1 Prescription Competitor
  • Currently Available Nationwide at Walgreen's and CVS/pharmacy stores
  • Launching Marketing and Distribution Campaign
  • Expanding Retail-Chain-Store Distribution
  • Holds Patent on Product
  • 38 Million Shares Outstanding
  • Market Cap just under $1 Million

Current Valuation
As of May 14, 2013, PuraMed BioScience had approximately 37.9 million common shares outstanding, thus giving the stock a market cap valuation of an estimated $721,756.

PuraMed BioScience currently has LipiGesic® M, an over-the-counter migraine pain reliever, distributed in Walgreens and CVS/pharmacy stores nationwide. The Company plans to expand that retail placement to an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as selected regional drugstore chains.

Revenue Potential
With an estimated 39 million Americans suffering from migraine headaches, the revenue prospects for PuraMed BioScience could be explosive.

"The first thing to consider is that people who suffer the excruciating pain of migraine are actively looking for a product that will relieve their migraine pain and associated symptoms," said Russ Mitchell , CEO of PuraMed BioScience. "The second point to consider is that LipiGesic M has been shown to be highly effective and works as well as the number-one-selling prescription migraine treatment without the severe side effects often caused by chemical compounds. Since it is an OTC product, LipiGesic M is available without a doctor's prescription at far less cost. This availability will be increasingly important as insurance premiums, co-pays and deductibles continue to rise in response to changes prompted by the Affordable Care Act."

Thus, if PMBS gains 1% of the migraine market that would result in approximately 400,000 consumers buying LipiGesic M at a retail price of $19.95; that equates to nearly $8 million in sales.

In addition, consumers with acute migraines that recur two to three times a month who find LipiGesic M an effective migraine relief product would be expected to buy nine (9) boxes per year creating a potential of $72 million in annual sales.

These numbers are calculated based on just 1% of the migraine market.

To view the full report, and access risks, disclosures, and potential outlook visit http://www.wallstreetnewscast.com/profile/pmbs.html

About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic® M, PuraMed BioScience plans to launch LipiGesic® H for tension-type headaches and LipiGesic® PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com

Forward-Looking Statements
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
Melissa Diaz ,
South Street Media, Inc
Phone: (917) 937-8968
Email: info@southstreetmedia.com

 


'/>"/>
SOURCE PuraMed BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO
2. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
3. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
4. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
5. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
6. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
7. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
8. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
9. Ohios Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State
10. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
11. Roka Bioscience Secures $47.5 Million in Series D Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , ... April 25, 2017 , ... ... leading supplier of Common Lisp (CL) development tools, and market leader for ... includes key performance enhancements now available within the most effective system for developing ...
(Date:4/25/2017)... ... April 25, 2017 , ... Dr. Robert ... P.A. , proudly announced today that acclaimed physiatrist Matthew Terzella, MD, has joined ... 15, 2017. , Dr. Terzella completed his residency in Physical Medicine and Rehabilitation ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... denaturation in a cellular milieu; however, the broad application of this cellular target ... platforms with sensitive quantitative readouts. Cell-based thermal stabilization assays are valuable methods for ...
(Date:4/21/2017)... Austin, TX (PRWEB) , ... April 21, 2017 , ... ... more than a year, Formaspace is pleased to introduce it to top lab design ... Carolina. Formaspace CEO Jeff Turk and VP of Industrial Design and Engineering Greg Casey ...
Breaking Biology Technology:
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited ... to the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... the largest German biometrics company the two government leaders could see the ... well as DERMALOG┬┤s multi-biometrics system.   Continue Reading ... ...
(Date:3/13/2017)... 2017 Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or ... individuals. (PRNewsFoto/Dermalog Identification Systems) ... "Face Matching" is the fastest software for biometric Face Matching on the market. ...
(Date:3/7/2017)... England , March 7, 2017 Brandwatch , ... chosen by The Prince,s Trust to uncover insights to ... across The Trust. The UK,s leading youth charity will ... social campaign results and get a better understanding of the topics ... ...
Breaking Biology News(10 mins):